ZimVie Inc. (ZIMV)
NASDAQ: ZIMV · Real-Time Price · USD
18.85
0.00 (0.00%)
Aug 14, 2025, 2:06 PM - Market open
ZimVie Revenue
ZimVie had revenue of $116.66M in the quarter ending June 30, 2025, a decrease of -0.13%. This brings the company's revenue in the last twelve months to $443.40M, down -2.20% year-over-year. In the year 2024, ZimVie had annual revenue of $449.75M, down -1.68%.
Revenue (ttm)
$443.40M
Revenue Growth
-2.20%
P/S Ratio
1.18
Revenue / Employee
$250,510
Employees
1,770
Market Cap
531.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 449.75M | -7.68M | -1.68% |
Dec 31, 2023 | 457.43M | -5.86M | -1.26% |
Dec 31, 2022 | 463.29M | -9.02M | -1.91% |
Dec 31, 2021 | 472.31M | -440.12M | -48.24% |
Dec 31, 2020 | 912.43M | -143.07M | -13.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZIMV News
- 14 days ago - ZimVie Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 20 days ago - ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025 - GlobeNewsWire
- 21 days ago - ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China - GlobeNewsWire
- 22 days ago - ZIMVIE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ZimVie Inc. - ZIMV - Business Wire
- 24 days ago - ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash - GlobeNewsWire
- 2 months ago - ZimVie: Screening Cheap (Rating Upgrade) - Seeking Alpha
- 2 months ago - ZimVie Announces Launch of RealGUIDE® Dental Implant Software Suite and Implant Concierge® Service in Japan - GlobeNewsWire
- 3 months ago - ZimVie to Participate in the Stifel 2025 Jaws & Paws Conference - GlobeNewsWire